Enterome’s Global Licensing, Co-Development and Co-Promotion Agreement with Takeda


Goodwin advised Enterome on the transaction

Enterome SA, a clinical-stage biotech company developing innovative therapies to treat microbiome-associated diseases with a focus on auto-immune disease and cancer, has entered into a global licensing, co-development and co-promotion agreement with Takeda Pharmaceutical Company Limited. The agreement covers Enterome’s lead investigational drug candidate EB8018 in patients with Crohn’s disease, with the potential to expand to other gastrointestinal (GI) disorders and liver diseases.

Enterome will receive an upfront payment of $50 million and a commitment from Takeda to make a future equity investment in the Company. Enterome is also eligible to receive up to $640 million for achieving specified clinical development, regulatory and commercial milestones with EB8018. In addition, Enterome and Takeda will co-develop EB8018 under the joint agreement and, if approved, the product will be co-promoted in the US under a profit/cost sharing structure. Takeda will receive an exclusive license to commercialize EB8018 outside of the US, and Enterome will be eligible to receive royalties on net sales generated in these territories.

EB8018 is a novel, first-in-class, orally administered, gut-restricted small molecule designed to selectively disarm virulent bacteria in the gut that can cause inflammation without disrupting the local microbiome. EB8018 inhibits FimH-mediated inflammation induced by interaction of pathogenic pro-inflammatory bacteria to receptors in the gut wall, thereby potentially reducing the production of inflammatory cytokines including TNF. FimH was validated as a novel microbiome-derived therapeutic target by Enterome through application of its proprietary metagenomics platform, EB8018 was originally discovered by Vertex Pharmaceuticals, Inc.

EB8018 successfully completed a Phase 1a trial, where the study results demonstrated that administration of EB8018 in the dose range examined was safe and exhibited minimal blood absorption.

The Goodwin team was led by partner Jonathan Schur and included partners Theresa Kavanaugh (Picture), Julie Tibbets and Paul Jin, as well as associates Emily Beman and Mayan Katz. Enterome was also advised by Luc Barny of the Strasbourg bar.

Involved fees earner: Emily Beman – Goodwin Procter; Paul Jin – Goodwin Procter; Mayan Katz – Goodwin Procter; Theresa Kavanaugh – Goodwin Procter; Jonathan Schur – Goodwin Procter; Julie Tibbets – Goodwin Procter;

Law Firms: Goodwin Procter;

Clients: Enterome Bioscience;

Author: Ambrogio Visconti